Please use this identifier to cite or link to this item:
|Title:||Chloroquine for influenza prevention: A randomised, double-blind, placebo controlled trial||Authors:||Paton, N.I.
|Issue Date:||Sep-2011||Citation:||Paton, N.I., Lee, L., Xu, Y., Ooi, E.E., Cheung, Y.B., Archuleta, S., Wong, G., Smith, A.W. (2011-09). Chloroquine for influenza prevention: A randomised, double-blind, placebo controlled trial. The Lancet Infectious Diseases 11 (9) : 677-683. ScholarBank@NUS Repository. https://doi.org/10.1016/S1473-3099(11)70065-2||Abstract:||Background: Chloroquine has in-vitro activity against influenza and could be an ideal candidate for worldwide prevention of influenza in the period between onset of a pandemic with a virulent influenza strain and the development and widespread dissemination of an effective vaccine. We aimed to assess the efficacy of such an intervention. Methods: In this randomised, double-blind, placebo-controlled trial done at a single centre in Singapore, we randomly assigned (1:1) healthy adults to receive chloroquine phosphate (500 mg/day for 1 week, then once a week to complete 12 weeks) or matching placebo by use of a computer-generated randomisation list. Participants filled an online symptom diary every week, supplemented by daily diaries and self-administered nasal swabs when unwell. Haemagglutination-inhibition assays for influenza A (H1N1, H3N2) and B were done on blood samples taken at baseline and after 12 weeks. The primary outcome was laboratory-confirmed clinical influenza defined by specific symptoms accompanied by influenza RNA on nasal swabs or a four-fold increase in haemagglutination-inhibition titres over the 12-week study period. Analysis was by intention to treat. This trial was registered with ClinicalTrials.gov, number NCT01078779. Findings: From November, 2009, to February, 2010, we recruited 1516 eligible participants. 1496 (96%) returned at week 12 and were included in the efficacy analysis. Adherence to study intervention was 97%, and 94% of the scheduled weekly diaries were completed. Eight (1%) of 738 participants had laboratory-confirmed clinical influenza in the placebo group and 12 (2%) of 724 in the chloroquine group (relative risk 1·53, 95% CI 0·63-3·72; p=0·376). 29 (4%) of 738 had laboratory-confirmed influenza infection (symptomatic or asymptomatic) in the placebo group and 38 (5%) of 724 in the chloroquine group (1·34, 0·83-2·14; p=0·261). 249 (33%) of 759 participants reported adverse events (mostly mild) in the placebo group and 341 (45%) of 757 in chloroquine group (p||Source Title:||The Lancet Infectious Diseases||URI:||http://scholarbank.nus.edu.sg/handle/10635/109963||ISSN:||14733099||DOI:||10.1016/S1473-3099(11)70065-2|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Oct 22, 2020
WEB OF SCIENCETM
checked on Oct 22, 2020
checked on Oct 23, 2020
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.